Core Insights - HBC reported total operating revenues of NOK 60.9 million in Q1 2025, a 15% increase from NOK 52.4 million in Q1 2024, driven by growth in higher-margin human and pet health segments despite production constraints and commodity oil market pressures [1][6] - The company experienced a significant increase in B2B sales in the human segment, with a 66% year-over-year growth, particularly for products like OmeGo® and ProGo® [6] - HBC launched an unsecured bond that closed after the quarter with subscriptions of approximately CHF 3.5 million, indicating strong investor interest [6] Financial Performance - Cost of goods sold (CoGS) rose to NOK 37.5 million from NOK 27.3 million in Q1 2024, while operating expenses slightly decreased to NOK 23.1 million from NOK 23.9 million [2] - EBITDA for the quarter was negative NOK 19.9 million, compared to NOK -16.2 million in Q1 2024, with operational EBITDA at NOK -8.3 million [3] - The first quarter included NOK 3.0 million in one-time restructuring costs aimed at improving long-term operational efficiency [2][3] Product and Market Developments - HBC's product offerings include ProGo®, OmeGo®, and CalGo® / NT-II®, which are designed to enhance human and pet health [5] - The company achieved a record production period at its Midsund facility, operating 15-20% above its rated capacity while maintaining quality [6] - Clinical studies have shown that OmeGo® significantly reduces coughing and improves sleep in individuals exposed to pollution, while NT-II™ demonstrated improvements in joint pain and stiffness [6][7] Strategic Initiatives - HBC is expanding its production capacity at Berkåk to triple output, reflecting confidence in future demand [6] - The company has made significant advances in pharmaceutical research, including programs targeting prostate cancer and asthma, and has established a biotech-focused spin-off, HBC Immunology [7] - HBC participated in major industry events, reinforcing its leadership in marine-based nutrition and expanding its market presence [6]

P3 Health Partners (PIII) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Ryan Halsted - Managing DirectorAric Coffman - CEOLeif Pedersen - Chief Financial OfficerAmir Bacchus - Co-Founder and Chief Medical OfficerAaron Wukmir - Healthcare Equity Research AssociateJoshua Raskin - Partner - Managed Care & Providers Conference Call Participants Ryan Langston - Director & Senior Analyst - Healthcare Research Operator Good day, and welcome to the P3 Health Partners First Quarter twenty twent ...

P3 Health Partners (PIII) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Good day, and welcome to the P3 Health Partners First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Brian Halstead. Please go ahead. Speaker1 Thank you, operator, and thank you for joining us today. Before we proceed with the call, I would like to remind everyone that certain statements ...

Costco Wholesale Corporation (COST) and Dollar General Corporation (DG) stand out prominently in the Retail–Discount Stores industry. Costco boasts a substantial market capitalization of approximately $440 billion, operating on a membership-based warehouse model focused on selling bulk goods at discounted prices. The company manages a network of 905 warehouses globally, including 624 in the United States.In contrast, Dollar General holds a market capitalization of around $19.3 billion and operates a vast ne ...

Core Insights - Odysight.ai Inc. reported significant growth in revenues and a strong cash position, indicating progress in its business strategy and operational foundations [4][8][3] Financial Performance - Revenues for the three months ended March 31, 2025, were approximately $2.1 million, a substantial increase from $0.2 million in the same period in 2024, primarily due to a contract with a Fortune 500 medical company [4] - Cost of revenues increased to $1.5 million from $0.4 million year-over-year, driven by contract fulfillment costs and inventory impairment [5] - Gross profit was $0.6 million, reflecting a gross margin of 26%, compared to a gross loss of $0.2 million in the prior year [6] - Operating expenses rose to $5.1 million from $3.1 million, largely due to operational expansion and one-time uplisting expenses [7] - The net loss for the quarter was $4.3 million, compared to a net loss of $3.2 million in the same quarter of 2024 [7] Cash Position and Capital Raise - The company had a net cash position of approximately $37.2 million as of March 31, 2025, up from about $17.0 million a year earlier [2][8] - In February 2025, Odysight.ai uplisted to the Nasdaq Capital Market and raised gross proceeds of approximately $23.7 million through a public offering [8][9] Business Developments - The company has established partnerships, including one with Israel Railways to develop an AI-powered visualization system aimed at enhancing railway safety [9] - An initial purchase order was received from a European partner for a combined industrial solution utilizing Odysight.ai's technology [9] Backlog - The backlog as of March 31, 2025, was approximately $14.8 million, indicating future revenue potential [4][16]

Cloud-based Solution Optimizes the Online Search Experience With Near Real-time Access to Data to Increase Efficiency of Marketing Efforts and Drive SalesATLANTA, May 15, 2025 /PRNewswire/ -- Equifax® (NYSE: EFX) has launched its B2bConnect small-to-medium sized business (SMB) data on the Equifax Cloud™, making commercial marketing data available in minutes to help B2B marketers be more efficient and increase campaign success. The platform unifies differentiated data to create more effective commercial sale ...

WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced findings from its annual Hospital Operations Outlook Survey of more than 200 senior executives across all types of hospitals. The survey found rising costs, patient wait times, workforce challenges and persistent cybersecurity threats are among the top issues highlighted by hospital leaders. These issues — bundled with an increasingly complex operating environment shaped by regulatory changes, such as potential Med ...

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q1 2025 and the of the Company’s milestone of achieving its first profitable quarter. Management Commentary: "Starting 2025 with positive momentum, we are proud to report our first profitable quarter—a m ...

Codexis (CDXS) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to your host, Carrie McKim, Director of Investor Relations. Carrie, please go ahead. Speaker1 Thank you, operator. With me today are Doctor. Stephen Dilly, Codexis' Chairman and Chief Executive Officer Georgia Erbez, Chief Financial Officer and Doctor. Stephane Lutz, Senior Vice President of Research. During this call, management will making a nu ...

Core Insights - The Oncology Institute, Inc. (TOI) reported a strong start to 2025, with expectations for sustained cash flow positivity and profitability in the second half of the year, driven by operational efficiencies and strategic market expansion [4][5][6] - The company anticipates adding approximately $50 million in new revenue from new capitation contracts projected for the first half of 2025, with a potential increase of 100,000 lives in the second half of the year [4][6] Recent Operational Highlights - TOI achieved consolidated revenue of $104.4 million in Q1 2025, a 10.3% increase from $94.7 million in Q1 2024 [8] - The retail pharmacy and dispensary segment generated $49.3 million in revenue, growing over 20% year-over-year [6][9] - Fee-for-service revenue grew by 9% in Q1 2025 compared to Q4 2024, reflecting investments in referral management and call center expansion [6] Financial Performance - Gross profit for Q1 2025 was $17.2 million, a 44.1% increase from the prior year quarter [10] - The net loss for Q1 2025 was $19.6 million, slightly improved from a net loss of $19.9 million in Q1 2024 [12] - Adjusted EBITDA improved to $(5.1) million in Q1 2025 from $(10.9) million in Q1 2024 [12][20] Guidance for Fiscal Year 2025 - TOI expects full-year revenue to be between $460 million and $480 million, with gross profit projected between $73 million and $82 million [7] - The company anticipates Adjusted EBITDA to range from $(8) million to $(17) million for the year [7] Key Business Metrics - As of March 31, 2025, TOI operated 81 clinics across 18 markets, serving approximately 1.9 million lives under value-based contracts [32] - Cash and cash equivalents stood at $39.7 million as of March 31, 2025, down from $49.7 million at the end of 2024 [33]